Bowen Zhu

Bowen Zhu

Auto-generated profile, based on publicly available information

Bowen Zhu

Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University No.58 Zhongshan 2nd Rd, Guangzhou 510080, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ZPZhenwei Peng
Zhenwei Peng
WFWenzhe Fan
Wenzhe Fan
BZBowen Zhu
Bowen Zhu
GWGuoying Wang
Guoying Wang
JSJun-Hui Sun
Jun-Hui Sun
MKMing Kuang
Ming Kuang
PURPOSE: Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN monotherapy in patients with advanced HCC.MATERIALS AND METHODS: This was a multicenter, randomized, open-label, parallel group, phase III trial. Patients with primary treatment-naive or initial recurrent advanced HCC after surgery were randomly assigned (1:1) to receive LEN plus on-demand TACE (LEN-TACE) or LEN monotherapy. LEN was initiated within 3 days after random assignment (initial dose: 12 mg once daily for patients ≥ 60 kg; 8 mg once daily for patients < 60 kg). TACE was initiated one day after LEN initiation. The primary end point was overall survival (OS).RESULTS: Between June 2019 and July 2021, a total of 338 patients underwent random assignment at 12 centers in China: 170 to LEN-TACE and 168 to LEN. At a prespecified event-driven interim analysis after a median follow-up of 17.0 months, the median OS was significantly longer in the LEN-TACE group (17.8 v 11.5 months; hazard ratio, 0.45; P < .001). The median progression-free survival was 10.6 months in the LEN-TACE group and 6.4 months in the LEN group (hazard ratio, 0.43; P < .001). Patients in the LEN-TACE group had a higher objective response rate according to the modified RECIST (54.1% v 25.0%, P < .001). Multivariable analysis revealed that portal vein tumor thrombus and treatment allocation were independent risk factors for OS.CONCLUSION: The addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC.

1 May 2025 in Radiology
Verified
Journal Article
Closed access
HLHaikuan Liu
Haikuan Liu
WFWenzhe Fan
Wenzhe Fan
HLHaiqing Li
Haiqing Li
LQLiangliang Qiao
Liangliang Qiao
ZLZhilong Liu
Zhilong Liu
JLJiaping Li
Jiaping Li
Compared with epirubicin, idarubicin increased survival rates in participants with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization without an increase adverse event incidence.

6 July 2024 in Cancer Medicine
Verified
Journal Article
Open access
WFWenzhe Fan
Wenzhe Fan
XZXinlin Zheng
Xinlin Zheng
XZXiao Zhao
Xiao Zhao
BZBowen Zhu
Bowen Zhu
YWYanqin Wu
Yanqin Wu
JLJiaping Li
Jiaping Li
Background: Transarterial chemoembolization (TACE) is the standard treatment for intermediate‐stage hepatocellular carcinoma (HCC). Given the lack of specific recommendations for conventional TACE (cTACE) and drug‐eluting bead TACE (DEB‐TACE) in patients having unresectable HCC with tumor infiltrating the common hepatic duct or the first‐order branch of the bile ducts (B1‐type bile duct invasion; B1‐BDI) after biliary drainage, we retrospectively compared the safety and efficacy of DEB‐TACE with cTACE in this patient population.Materials and Methods: Using data from five tertiary medical centers (January 2017–December 2021), we compared complications, overall survival (OS), time to progression (TTP), and tumor response rate between patients having unresectable HCC with B1‐BDI who underwent DEB‐TACE or cTACE after successful biliary drainage. X‐tile software calculated the pre‐TACE total bilirubin (TBil) cutoff value, indicating optimal timing for sequential TACE after drainage. Propensity score matching (PSM) was performed.Results: The study included 108 patients with unresectable HCC (B1‐BDI) who underwent DEB‐TACE and 114 who received cTACE as initial treatment. After PSM (n = 53 for each group), the DEB‐TACE group had a longer TTP (8.9 vs. 6.7 months, p = 0.038) and higher objective response rate (64.2% vs. 39.6%, p = 0.011) than did the cTACE group, although OS was comparable (16.7 vs. 15.3 months, p = 0.115). The DEB‐TACE group exhibited fewer post‐procedural increments in the mean albumin‐bilirubin score, TBil, and alanine aminotransferase (ALT), along with a significantly lower incidence of serious adverse events within 30 days (hepatic failure, ALT increase, and TBil increase) than the cTACE group (all p < 0.05). The pre‐TACE TBil cutoff value was 99 μmol/L; patients with higher values (>99 μmol/L) had poorer OS in both groups (p < 0.05).Conclusion: DEB‐TACE is safe and effective after successful biliary drainage in unresectable HCC with B1‐BDI, potentially better than cTACE in terms of liver toxicity, TTP, and ORR. Lowering TBil below 99 μmol/L through successful drainage may create ideal conditions for sequential TACE.

1 March 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
WFWenzhe Fan
Wenzhe Fan
XZXinlin Zheng
Xinlin Zheng
WZWeihong Zhang
Weihong Zhang
BZBowen Zhu
Bowen Zhu
YWYanqin Wu
Yanqin Wu
JLJiaping Li
Jiaping Li
Purpose: Central bile duct invasion (BDI) by hepatocellular carcinoma (HCC) is rare and associated with poor prognosis, lacking treatment guidelines. While transarterial chemoembolization (TACE) is often used for unresectable cases, determining optimal candidates post-biliary drainage is controversial. We aim to develop a prognostic prediction model for unresectable HCC (uHCC) patients with central BDI receiving sequential TACE after successful biliary drainage. Patients and Methods: We retrospectively analyzed 267 uHCC patients with central BDI receiving successful biliary drainage and sequential TACE from seven tertiary centers (2015– 2021), divided into training (n=187) and validation (n=80) sets. Using Cox proportional-hazards regression model, we identified key prognostic indicators for overall survival (OS) and constructed a prediction model. Results: Pre-TACE total bilirubin (TBil) values, extrahepatic spread (EHS), multiple intrahepatic tumors (MIT), and portal vein tumor thrombus (PVTT) were identified as the significant clinical indicators for OS. These four parameters were included in a novel prediction model, named TEMP score, which could successfully categorize patients in the training set into three distinct risk grades with median OS of 26.9, 9.4, and 5.8 months, respectively. The TEMP score predicted the time-dependent areas under the receiver operating characteristic curves for OS at 6 months, 1 year, and 2 years of 0.813/0.907, 0.833/0.782, and 0.838/0.811 in the training and validation sets, with corresponding C-indices of 0.812/0.929, 0.829/0.761, and 0.818/0.791, respectively, outperforming other currently available models in both cohorts. The calibration curve of the model for predicting OS presented good consistency between observations and predictions in both the training set and validation set. Conclusion: The TEMP score effectively stratifies the prognosis of uHCC patients with central BDI who have undergone successful bile drainage and sequential TACE, helping to identify those who may benefit from TACE treatment.

1 September 2006 in Fertility and Sterility
Verified
Journal Article
Open access
PDF file
EZE.H. Zhang
E.H. Zhang
XLX.Y. Liang
X.Y. Liang
JDJ. Du
J. Du
BZB. Zhu
B. Zhu
GZG.L. Zhuang
G.L. Zhuang
To investigate the relationship among ultrasonographic features of endomtrium, histological staging of the endometrium and sexual hormone levels in anovulatory polycystic ovary syndrome (PCOS) women.